Modern Setup Host Windows 10
Kroger Feedback

Blog

Live Blog | SDPA Summer Conference 2016

LIVE BLOG | You’ve Got Options: The Changing Paradigm of Plaque Psoriasis

In this live blog from the SDPA Annual Summer Dermatology Conference in Austin, TX, Colby Evans, presented a product theater for Celgene called, “You’ve Got Options: The Changing Paradigm of Plaque Psoriasis.

Highlights:

  • Otezla (apremilast) is approved for the treatment of patients with moderate to severe plaque psoriasis and for the treatment of adult patients with active psoriatic arthritis.
  • Otezla was shown to be effective in patients with moderate to severe plaque psoriasis. 33 % of patients taking Otezla achieved PASI-75 response vs. 5% of those taking placebo.
  • Otezla was also shown to be effective in adult patients with active psoriatic arthritis.
  • Otezla is an oral drug that works inside the cell to regulate inflammatory mediators.
  • Otezla does not require laboratory monitoring and has no contraindications other than for patients who are allergic to the drug.

More:

Dr. Evans spoke at SDPA’s summer conference about Otezla (apremilast), an oral medication for the treatment of moderate to severe plaque psoriasis and for the treatment of adults with active psoriatic arthritis.

He discussed the results from the ESTEEM 1 trial that showed over 33% of patients taking Otezla achieved a PASI-75 response versus 5% of those taking placebo. Dr. Colby added that results were similar in the ESTEEM 2 trial, with almost 30% of patients who took Otezla achieving PASI-75 at week 16 compared to 5% who took placebo.

Dr. Evans noted that Otezla was also shown to be effective in the treatment of adults with active psoriatic arthritis. In a clinical trial, 38% of patients taking Otezla achieved a significant improvement in ACR-20 response compared to 19% who took placebo.

Dr. Evans explained that Otezla is a drug that works inside the cell to regulate inflammatory mediators. He stressed that Otezla is not a biologic and does not require laboratory monitoring. He added that Otezla has no contraindications except for patients who are allergic to the drug itself.

He discussed the most common side effects were diarrhea and nausea, which tended to resolve with time. Dr. Evans also mentioned that 1.3% of participants taking Otezla reported depression compared to 0.4% taking placebo in clinical trials.